Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Initial 2,500-metre program targets high-grade shoots in Chevrier Main deposit

For veteran speculators, the latest hits to junior mining share prices feels like deja vu all over again. Sentiment is gloomy and market capitalizations are depressed. But gold in U.S. dollar terms is still up more than 25% year-over-year. And US$1,500 gold translates to m...
James Kwantes | March 18, 2020 |

Regeneron Shares Rise 10% on Advances in its Novel COVID-19 Antibody Program

Shares of Regeneron Pharmaceuticals rose to a new 52-week high price after the company reported it has identified hundreds of virus-neutralizing antibodies and plans to initiate large-scale manufacturing by mid-April of a multi-antibody therapy to treat coronavirus. ...
Streetwise Reports | March 18, 2020 |

Clinical Program Started for Agitation with Schizophrenia, Bipolar Disorder

The design of and an opinion on the included studies are provided in an H.C. Wainwright & Co. report. In a Dec. 30 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that BioXcel Therapeutics Inc. (BTAI:NASDAQ) launched its pivotal trial program for...
Streetwise Reports | January 6, 2020 |

Where Today’s Leading-Edge Technology Meets a Historical Gold Mine

When Stockhouse Editorial last caught up with Ron Coombes , the President, Chief Executive Officer and Director of Providence Gold Mines Inc. (PHD) ( TSX-V.PHD , OTC: PRRVF , Forum ), he mentioned that a top geologist once told him the simple but wise words, “Gold is...
Dave Jackson | December 4, 2020 |

NCI Chooses Veterinary Biopharma as Select Manufacturing Contractor

The contract's meaning, terms and benefits and the California firm's near-term catalysts are discussed in an H.C. Wainwright & Co. report. In a Sept. 12 research note, H.C. Wainwright & Co. analyst Swayampakula Ramakanth reported that Kindred Biosciences Inc. (KIN:NA...
Streetwise Reports | September 19, 2019 |

NV Gold identifies large, structural target for August drilling

NV Gold (TSX-V:NVX, US:NVGLF) has determined where it will plant the first drill rig this summer, among a thick portfolio of over a dozen gold projects in Nevada. The Slumber property in the Jackson Mountains, located about 50 miles northwest of Winnemucca, Humboldt Count...
Richard (Rick) Mills | July 19, 2019 |

Central Banks Fire Bazooka at Coronavirus. Will Gold Rally?

The new coronavirus has already infected the global economy. The global lockdown means that recession is inevitable. The central banks all over the world have stepped in, including the Fed, cutting interest rates and pumping liquidity into the system. We invite you thus ...
Arkadiusz Sieron | April 20, 2020 |

Applied Therapeutics Investors Like the ACTION in Phase 2 Galactosemia Study

Applied Therapeutics' shares traded 25% higher today after the company reported positive topline results from its Pivotal Phase 2 ACTION Study of AT-007 for use in the treatment of galactosemia. The firm expects to file for regulatory approval of AT-007 in H2/20. This...
Streetwise Reports | January 9, 2020 |

AIM ImmunoTech Shares Soar as Japan's NIID Tests Ampligen® as Potential Coronavirus Treatment

Shares of AIM ImmunoTech traded more than 150% higher after the company reported that Japan's National Institute of Infectious Diseases will test its Ampligen® drug as a potential treatment for the coronavirus. Immuno-pharmaceutical company AIM Imm...
Streetwise Reports | March 10, 2020 |

Meeting the New Green Economy’s Voracious Appetite for Lithium

(Click image to play video) As the battery metals market continues to skyrocket – and lithium in particular – new, reliable sources of this critical metal are in extremely high demand. Enter ION Energy Ltd. ( TSX-V. ION , OTCMKTS: IONGF , FF:5YB ) – an e...
Dave Jackson | April 19, 2021 |
1 2 3 4 5 6 7 8 9 10 ...